INTRAROSA

Drug AMAG Pharmaceuticals, Inc.
Total Payments
$10.3M
Transactions
64,813
Doctors
16,555
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2024 $42,124 2,229 1,587
2023 $15,740 873 631
2022 $4,109 155 139
2021 $8,874 420 341
2020 $5,869 279 252
2019 $1.6M 12,075 6,408
2018 $7.5M 33,343 10,769
2017 $1.1M 15,439 8,179

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $6.2M 1,243 60.2%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2.2M 1,113 21.4%
Education $736,797 50,685 7.1%
Food and Beverage $528,540 9,418 5.1%
Travel and Lodging $405,097 2,221 3.9%
Consulting Fee $174,284 102 1.7%
Space rental or facility fees (teaching hospital only) $45,880 26 0.4%
Grant $7,150 3 0.1%
Gift $180.00 2 0.0%

Payments by Type

Research
$6.2M
1,243 transactions
General
$4.1M
63,570 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
PRASTERONE DHEA FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER HSDD AMAG Pharmaceuticals, Inc. $4.9M 0
Prasterone DHEA for the Treatment of Hypoactive Sexual Desire Disorder HSDD - Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone AMAG Pharmaceuticals, Inc. $1.0M 0
PRASTERONE DHEA FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER HSDD - SECOND STUDY AMAG Pharmaceuticals, Inc. $104,530 0
Open label Pilot Vulvoscopy Photography Study AMAG Pharmaceuticals, Inc. $66,341 0
OPEN LABEL PILOT VULVOSCOPY PHOTOGRAPHY STUDY AMAG Pharmaceuticals, Inc. $66,341 0
A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone DHEA, Intrarosa on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause AMAG Pharmaceuticals, Inc. $37,669 0
Possible Effect of INTRAROSA Therapy on Bladder Function AMAG Pharmaceuticals, Inc. $25,671 0

Top Doctors Receiving Payments for INTRAROSA

Doctor Specialty Location Total Records
Eileen Cutler — New York, NY $6.3M 1,277
, MD Obstetrics & Gynecology Columbus, OH $210,342 279
, MD Urology San Diego, CA $184,888 286
, MD Obstetrics & Gynecology Woodland Hills, CA $169,019 312
, MD Gynecology Kenmore, NY $120,224 343
, M.D Reproductive Endocrinology Washington, DC $115,596 208
, MD Obstetrics & Gynecology Saint Louis, MO $105,942 201
, MD Obstetrics & Gynecology Hartford, CT $104,946 230
, MD Obstetrics & Gynecology Gilbert, AZ $94,312 182
, MD Gynecology Lutherville, MD $90,238 156
, MD Gynecology Waco, TX $80,059 154
, M.D., FACOG Obstetrics & Gynecology New Haven, CT $60,780 110
, M.D, Obstetrics & Gynecology Berkeley, CA $55,949 74
, MD Gynecology Charlotte, NC $55,334 119
, MD Obstetrics & Gynecology Cullman, AL $54,944 115
, M.D Internal Medicine Boston, MA $54,936 12
, M.D Reproductive Endocrinology New York, NY $53,028 70
, MD Obstetrics & Gynecology Chesapeake, VA $52,763 118
, M.D Gynecology Greenacres, FL $47,750 91
, MD Gynecology Williamsville, NY $43,654 82
David Gandell — Rochester, NY $41,514 76
, M.D Gynecology Aventura, FL $41,063 119
, MD Gynecology Newport Beach, CA $38,925 91
, D.O Gynecology Tulsa, OK $38,638 70
, MD Obstetrics & Gynecology Savannah, GA $37,184 73
123…663»

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $10.3M
  • Total Doctors 16,555
  • Transactions 64,813

About INTRAROSA

INTRAROSA is a drug associated with $10.3M in payments to 16,555 healthcare providers, recorded across 64,813 transactions in the CMS Open Payments database. The primary manufacturer is AMAG Pharmaceuticals, Inc..

Payment data is available from 2017 to 2024. In 2024, $42,124 was paid across 2,229 transactions to 1,587 doctors.

The most common payment nature for INTRAROSA is "Unspecified" ($6.2M, 60.2% of total).

INTRAROSA is associated with 7 research studies, including "PRASTERONE DHEA FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER HSDD" ($4.9M).